181 related articles for article (PubMed ID: 30915533)
21. Risk of mortality of node-negative, ER/PR/HER2 breast cancer subtypes in T1, T2, and T3 tumors.
Parise CA; Caggiano V
Breast Cancer Res Treat; 2017 Oct; 165(3):743-750. PubMed ID: 28689363
[TBL] [Abstract][Full Text] [Related]
22. Breast cancer subtype approximations and loco-regional recurrence after immediate breast reconstruction.
Kneubil MC; Brollo J; Botteri E; Curigliano G; Rotmensz N; Goldhirsch A; Lohsiriwat V; Manconi A; Martella S; Santillo B; Petit JY; Rietjens M
Eur J Surg Oncol; 2013 Mar; 39(3):260-5. PubMed ID: 23313014
[TBL] [Abstract][Full Text] [Related]
23. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
24. Influence of the subtype on local recurrence risk of breast cancer with or without radiation therapy.
Wickberg Å; Magnuson A; Holmberg L; Adami HO; Liljegren G
Breast; 2018 Dec; 42():54-60. PubMed ID: 30176553
[TBL] [Abstract][Full Text] [Related]
25. Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.
Cardoso F; Bartlett JMS; Slaets L; van Deurzen CHM; van Leeuwen-Stok E; Porter P; Linderholm B; Hedenfalk I; Schröder C; Martens J; Bayani J; van Asperen C; Murray M; Hudis C; Middleton L; Vermeij J; Punie K; Fraser J; Nowaczyk M; Rubio IT; Aebi S; Kelly C; Ruddy KJ; Winer E; Nilsson C; Lago LD; Korde L; Benstead K; Bogler O; Goulioti T; Peric A; Litière S; Aalders KC; Poncet C; Tryfonidis K; Giordano SH
Ann Oncol; 2018 Feb; 29(2):405-417. PubMed ID: 29092024
[TBL] [Abstract][Full Text] [Related]
26. Outcomes According to Breast Cancer Subtype in Patients Treated With Accelerated Partial Breast Irradiation.
Wilkinson JB; Shah C; Amin M; Nadeau L; Shaitelman SF; Chen PY; Grills IS; Martinez AA; Mitchell CK; Wallace MF; Vicini FA
Clin Breast Cancer; 2017 Feb; 17(1):55-60. PubMed ID: 27666436
[TBL] [Abstract][Full Text] [Related]
27. Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index.
Ono M; Tsuda H; Yoshida M; Shimizu C; Kinoshita T; Tamura K
Clin Breast Cancer; 2017 Feb; 17(1):41-47. PubMed ID: 27477822
[TBL] [Abstract][Full Text] [Related]
28. Breast cancer in Ethiopia: evidence for geographic difference in the distribution of molecular subtypes in Africa.
Hadgu E; Seifu D; Tigneh W; Bokretsion Y; Bekele A; Abebe M; Sollie T; Merajver SD; Karlsson C; Karlsson MG
BMC Womens Health; 2018 Feb; 18(1):40. PubMed ID: 29444670
[TBL] [Abstract][Full Text] [Related]
29. Young age is associated with ipsilateral breast tumor recurrence after breast conserving surgery and radiation therapy in patients with HER2-positive/ER-negative subtype.
Kim HJ; Han W; Yi OV; Shin HC; Ahn SK; Koh BS; Moon HG; You JH; Son BH; Ahn SH; Noh DY
Breast Cancer Res Treat; 2011 Nov; 130(2):499-505. PubMed ID: 21853352
[TBL] [Abstract][Full Text] [Related]
30. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry.
Park S; Koo JS; Kim MS; Park HS; Lee JS; Lee JS; Kim SI; Park BW
Breast; 2012 Feb; 21(1):50-7. PubMed ID: 21865043
[TBL] [Abstract][Full Text] [Related]
31. The association between biological subtype and locoregional recurrence in newly diagnosed breast cancer.
Gabos Z; Thoms J; Ghosh S; Hanson J; Deschênes J; Sabri S; Abdulkarim B
Breast Cancer Res Treat; 2010 Nov; 124(1):187-94. PubMed ID: 20814819
[TBL] [Abstract][Full Text] [Related]
32. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.
Parise CA; Bauer KR; Brown MM; Caggiano V
Breast J; 2009; 15(6):593-602. PubMed ID: 19764994
[TBL] [Abstract][Full Text] [Related]
33. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
[TBL] [Abstract][Full Text] [Related]
34. Intratumoral heterogeneity of macrophages and fibroblasts in breast cancer is associated with the morphological diversity of tumor cells and contributes to lymph node metastasis.
Tashireva LA; Denisov EV; Gerashchenko TS; Pautova DN; Buldakov MA; Zavyalova MV; Kzhyshkowska J; Cherdyntseva NV; Perelmuter VM
Immunobiology; 2017 Apr; 222(4):631-640. PubMed ID: 27916281
[TBL] [Abstract][Full Text] [Related]
35. Molecular class as a predictor of locoregional and distant recurrence in the neoadjuvant setting for breast cancer.
Vargo JA; Beriwal S; Ahrendt GM; Soran A; Johnson RR; McGuire K; Bhargava R
Oncology; 2011; 80(5-6):341-9. PubMed ID: 21791944
[TBL] [Abstract][Full Text] [Related]
36. Intrinsic subtypes and benefit from postmastectomy radiotherapy in node-positive premenopausal breast cancer patients who received adjuvant chemotherapy - results from two independent randomized trials.
Laurberg T; Tramm T; Nielsen T; Alsner J; Nord S; Myhre S; Sørlie T; Leung S; Fan C; Perou C; Gelmon K; Overgaard J; Voduc D; Prat A; Cheang MCU
Acta Oncol; 2018 Jan; 57(1):38-43. PubMed ID: 29172851
[TBL] [Abstract][Full Text] [Related]
37. Response to Radiotherapy After Breast-Conserving Surgery in Different Breast Cancer Subtypes in the Swedish Breast Cancer Group 91 Radiotherapy Randomized Clinical Trial.
Sjöström M; Lundstedt D; Hartman L; Holmberg E; Killander F; Kovács A; Malmström P; Niméus E; Werner Rönnerman E; Fernö M; Karlsson P
J Clin Oncol; 2017 Oct; 35(28):3222-3229. PubMed ID: 28759347
[TBL] [Abstract][Full Text] [Related]
38. The prognostic value of Ki67 in systemically untreated patients with node-negative breast cancer.
Pathmanathan N; Balleine RL; Jayasinghe UW; Bilinski KL; Provan PJ; Byth K; Bilous AM; Salisbury EL; Boyages J
J Clin Pathol; 2014 Mar; 67(3):222-8. PubMed ID: 24403187
[TBL] [Abstract][Full Text] [Related]
39. Breast Cancer Outcomes as Defined by the Estrogen Receptor, Progesterone Receptor, and Human Growth Factor Receptor-2 in a Multi-ethnic Asian Country.
Subramaniam S; Bhoo-Pathy N; Taib NA; Tan GH; See MH; Jamaris S; Ho GF; Looi LM; Yip CH
World J Surg; 2015 Oct; 39(10):2450-8. PubMed ID: 26138872
[TBL] [Abstract][Full Text] [Related]
40. [Prognosis and risk factors of 1 791 patients with breast cancer treated with breast-conserving surgery based on real-world data].
Chen SY; Tang Y; Song YW; Wang SL; Jin J; Liu YP; Wang WH; Fang H; Ren H; Sun GY; Wang JY; Jing H; Zhang JH; Liu XF; Yu ZH; Li YX
Zhonghua Zhong Liu Za Zhi; 2018 Aug; 40(8):619-625. PubMed ID: 30139034
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
